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Abstract: 
Background: Crimean-Congo hemorrhagic fever (CCHF) is an endemic disease in Turkey. The clinical presentation and 
laboratory findings are not specific especially in cases without hemorrhagic findings.
Objective: We aimed to evaluate CCHF cases and compare them with non-CCHF cases in terms of  their characteristics 
during admission.
Methods: Cases with a preliminary diagnosis of  CCHF at a secondary care hospital in Kastamonu in 2013 were evaluated, 
retrospectively. Cases testing RNA/IgM positive were considered as CCHF. Cases testing both RNA and IgM negative were 
considered as non-CCHF. The two groups were then compared in terms of  their clinical, laboratory and epidemiological 
characteristics during admission.
Results: A total of  41 cases were tested and CCHF was found in 46.3% of  cases. Fatality was 5.3% in CCHF cases. The 
frequency of  tick bites and CK elevation in CCHF cases was significantly higher than non-CCHF cases (p<0.05). There were 
no significant differences between the two groups regarding other characteristics (p>0.05).
Conclusions: In cases with a preliminary diagnosis of  CCHF, especially in cases without a history of  tick bite and with 
normal CK levels during admission, performing tests for the differential diagnosis may be advisable without waiting for the 
results of  tests for CCHF. 
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Introduction
Crimean-Congo  hemorrhagic  fever (CCHF)  is a tick-
borne  viral  zoonotic  infection acquired by a tick bite, 
transmitted from body fluids or blood of  domestic ani-
mals and cases with CCHF virus (CCHFV); this virus 
belongs to the genus Nairovirus in the family Bunyaviri-
dae.  The clinical spectrum of  the disease varies from a 
subclinical infection  to severe  disease  and death,  with 
a reported  fatality  rate of  15–30%  in human cases 1-10. 
It was reported in the Crimean Peninsula in 1944 for 
the first time11.  Since  then,  CCHF  has  been  reported 
from  different  parts  of   Africa,  Eastern Europe, the 
Balkans, the Middle East, Central and Southern Asia9, 
10, 12, 13. The first case of  CCHF infection in Turkey was 
reported in the Kelkit Valley region in 2002.
Turkey has become the country with the highest number 
of  CCHF cases among the countries that report CCHF 
cases annually. This infection is an endemic zoonosis 
appearing every year during spring and summer in Tur-
key with approximately 1000 cases reported annually 
1-10.  Majority of  cases in Turkey were from 15 cities 
in Kelkit Valley and its environs including Kastamonu 
Province. CCHF cases from countries that border Tur-
key including Bulgaria, Greece, Iran and Iraq have also 
been reported 6, 13-18. According to various studies, the 
fatality rate of  CCHF ranged from 15-30%. However, 
the crude fatality rate was 5% in 2002-2007 according 
to the reports of  the Turkish Ministry of  Health sur-
veillance 1-10.
There are a few studies evaluating cases with a pre-
liminary diagnosis of  CCHF and reporting the rate of  
confirmed CCHF cases among suspected CCHF cas-
es. This rate ranges between 21% and 57%19-22. In this 
study, cases of  CCHF admitted to a secondary  care 
hospital  in Kastamonu  in  2013  were  evaluated  in 
terms  of   their clinical, laboratory and epidemiological 
characteristics. Cases with CCHF were also compared 
in terms  of  these  characteristics  with  non-CCHF 
cases  whose  reverse transcriptase-polymerase chain 
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reaction  (RT-PCR)  and  ELISA  IgM  tests  were nega-
tive for CCHFV.
Methods
In  2013,  cases  admitted  with  a  preliminary  diagnosis 
of   CCHF  to  the  Dr  Münif  Islamoğlu Hospital (Kas-
tamonu Province, Turkey) were included in this study. A 
preliminary diagnosis of  CCHF was made if  cases pre-
sented with at least two of: (a) sudden  onset  of   high-
grade  fever;  (b)  headache;  (c)  weakness;  (d)  nausea 
and vomiting;  (e) diarrhea; and one of: (a) thrombocy-
topenia  (platelet count of  <150 x 109/L); and/or (b) 
leucopenia (white blood cell count of  <4 x 109/L); and 
also one of: (a) history  of  tick bite; (b) close  contact 
with animals;  (c) living  in rural areas  or travelling to 
rural areas; (d) being a laboratory worker; or (e) contact 
with people with similar symptoms in the past 15 days. 
Serum samples of  all cases were collected within 24 
hours of  admission and were sent to the Public Health 
Institution of  Turkey, National Virology Reference 
Laboratory to determine CCHF IgM antibodies by 
ELISA and CCHFV RNA by RT-PCR. ELISA was not 
performed on serum samples already detected by RT-
PCR as positive for viral RNA. Cases with viral RNA 
or IgM antibody positivite  were  considered  as  CCHF 
cases.  Cases  with  both  viral  RNA  and  IgM anti-
body  negative were considered  as non-CCHF  cases. 
Cases  with  a history  of  suspected CCHF in the past 
four months were excluded from the study because, se-
rum CCHF IgM antibodies detected by ELISA remain 
positive for four months after the infection 2, 4, 9, 10. The 
incubation period of  cases with tick exposure was de-
fined as the period between contact with tick and onset 
of  symptoms. Pediatric cases (≤16 ages) were excluded 
from the study. 
Moreover, there were no pediatric cases with a definite 
diagnosis  of  CCHF  in our hospital  in 2013.  CCHF 
cases  were evaluated retrospectively in terms of  their 
clinical and laboratory features during admission to the 
hospital and epidemiological features within 15 days, 
and these characteristics of  CCHF cases were com-
pared with non-CCHF cases.
Statistical analysis was performed using SPSS version 
15—0 (SPSS Inc., USA). Descriptive  statistics  (medi-
an,  minimum  and maximum  value, mean and standard 
deviation, count and percentage) were used to summa-
rize the results. Nominal variables were compared using 
χ2 test with Yates’ correction and Fisher’s exact test. 
Continuous variables were compared using Mann Whit-
ney U test. When a p-value was found less than 0.05, the 
result was considered as statistically significant and the 
null hypothesis was rejected.
Results
In 2013, a total of  41 cases with a preliminary diagnosis 
of  CCHF were followed up at our hospital. Three had a 
positive IgM by ELISA and 16 cases had a positive RT- 
PCR for CCHFV  RNA. A total of  19 cases (46.3%) 
were diagnosed  with definite CCHF. The remaining 22 
cases (53.7%) were found negative by both tests and 
were considered as non-CCHF cases. 52.6% (10) of  the 
CCHF cases were female, while 47.4% (9) were male. 
Besides, 54.5% (12) and 45.5% (10) of  the non-CCHF 
cases were female and male, respectively. The median 
age of  CCHF cases and non-CCHF cases was 54.0 (16-
83) and 51.5 (20-78), respectively.  There were no sta-
tistically significant differences between the two groups 
regarding gender and age (p> 0.05). Six cases from the 
CCHF group were transferred to a tertiary care hospi-
tal. One of  the transferred CCHF cases died while the 
other 18 cases were cured. Case who died was a 42 years 
old female patient with no comorbid diseases and the 
cause of  her death was multi organ failure. She did not 
receive ribavirin therapy. Thus, fatality rate was 5.3% 
(1/19) in the CCHF group. Three of  the transferred 
cases in the CCHF group and none of  non-CCHF cas-
es recieved oral ribavirin.
When looking at the monthly distribution of  the CCHF 
cases, it was shown that the first case was detected in 
April and the highest number of  cases was admitted in 
May (Figure 1). 
Figure 1: Monthly disturbution of  cases with a preliminary diagnosis of  Crimean-Congo hemorrhagic fever. 
Five cases were from Daday and four cases were from 
Devrekani and Taskopru  which  are  districts  of   Kas-
tamonu.  The  distribution  of   cases  with  a preliminary 
diagnosis of  CCHF by districts is shown in Figure 2.
Figure 2: The distribution of  cases with a preliminary diagnosis of  
Crimean- Congo hemorrhagic fever by districts. 
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In  both  groups,  the  most  common  clinical  symp-
toms   during  admission   were weakness, widespread 
muscle pain, fever, headache, nausea and vomiting, re-
spectively. The frequency of  abdominal pain, diarrhea 
and maculopapular rash was higher in CCHF cases. 
Bleeding  was observed in four (18.2%)  cases in the 
non- CCHF group during admission. There was no 
bleeding during admission in the CCHF group. There 
were no statistically significant differences between the 
two groups in terms of  clinical symptoms during ad-
mission (p> 0.05) (Table 1). 
The most common physical  finding  during admis-
sion  was fever,  which was present  in 68.4% (13) of  
CCHF and 50% (11) of  non-CCHF cases. In the CCHF 
group, five (26.3%) cases had maculopapular   rash, 
two   (10.5%)   had   altered   level   of    conscious-
ness   and hypotension, and one (5.3%) had ecchymo-
sis, petechiae and tachycardia during admission. In the 
non-CCHF group, four (18.2%) cases had hemorrhagic 
findings, three (13.6%) had tachycardia,  two (9.1%) 
had ecchymosis  and hypotension,  and one (4.5%) 
had maculopapular rash and altered level of  conscious-
ness. There was no statistically  significant  difference 
between  the two groups  in terms  of  physical find-
ings  during  admission  (p> 0.05). The most common 
laboratory  findings  in the cases with a preliminary 
diagnosis of  CCHF were thrombocytopenia, leukope-
nia, and aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) elevation, respectively.  94.7% 
(18) of  CCHF group and 95.5% (21) of  non-CCHF 
group had thrombocytopenia.  The proportion of  cases 
with platelet counts between 150-101 x 109/L, 100-51 
x 109/L and <51 x 109/L was 26.3%(5), 52.6% (10) 
15.8% (3) in the CCHF  group  and  54.5%(12),  27.3% 
(6) 13.6%  (3)  in  the  non-CCHF  group, respectively. 
While  elevated  creatine  phosphokinase  (CK)  and 
lactate dehydrogenase  (LDH)  levels  were  detected 
more  frequently  in the  CCHF  group, anemia was 
detected more frequently in the non-CCHF group. The 
frequency of  CK elevation in CCHF cases (57.9%) dur-
ing admission was significantly higher than non- CCHF 
cases (22.7%) (p<0.05). Other laboratory findings were 
similar between the two groups (p> 0.05) (Table 2).
within15 days before the onset of  symptoms. In non-
CCHF cases, these proportions were 86.4% (19), 77.3% 
(17) and 27.3% (6), respectively. In CCHF cases, a his-
tory of  tick bite in the last 15 days was significantly 
higher   than   non-CCHF    cases   (p<0.05).    Statisti-
cally    significant differences were not found between 
the two groups in terms of  other epidemiological char-
acteristics (p> 0.05) (Table 3).
When  the  cases  were  evaluated  according  to  their 
occupations,  majority  were farming-animal husbandry 
with 68.2% (15) and 73.7% (14) in the CCHF and the 
non- CCHF groups, respectively. The remaining cases 
had no occupational risk. Among CCHF cases,  94.7% 
(18) were living in rural areas, 89.5%  (17) had contact 
with animals and 84.2% (16) had a history of  tick bite 
Table 1: Clinical symptoms of  cases with a preliminary diagnosis of  
Crimean-Congo hemorrhagic fever during admission. 















Widespread muscle pain 94.7 (18) 86.4 (19) p>0.05 
Fever 84.2 (16) 72.7 (16) p>0.05 
Headache 84.2 (16) 72.7 (16) p>0.05 
Nausea and vomiting 84.2 (16) 68.2 (15) p>0.05 
Abdominal pain 36.8 (7) 31.8 (7) p>0.05 
Diarrhea 36.8 (7) 18.2 (4) p>0.05 
Maculopapular rash  26.3 (5) 18.2 (4) p>0.05 
Altered level of consciousness 10.5 (2) 4.5 (1) p>0.05 
Bleeding* 0.0 (0) 18.2 (4) p>0.05 
* Includes hematoma,hemoptysis,hematuria and nose, gingival, vaginal, gastrointestinal,  
intra-abdominal and intracranial bleeding. 
Table 2: The distribution of the laboratory findings of cases  with a  
preliminary diagnosis of Crimean-Congo hemorrhagic fever during admission. 















Platelet count ranges from:    
150-101 x 109/L 26.3 (5) 54.5 (12) p>0.05 
100-51 x 109/L 52.6 (10) 27.3 (6) p>0.05 
50.000-0 x 109/L 15.8 (3) 13.6 (3) p>0.05 
Leukopenia 89.5 (17) 63.6 (14) p>0.05 
AST-ALT elevation 84.2 (16) 59.1 (13) p>0.05 
LDH elevation 68.4 (13) 59.1 (13) p>0.05 
CK elevation 57.9 (11) 22.7 (5) P<0.05 
Anemia 47.4 (9) 63.6 (14) p>0.05 
INR elevation 38.8 (7) 22.7 (5) p>0.05 
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The mean incubation period of  cases with tick exposure 
was 3.8 ± 3.3 days in the CCHF group. The median 
day of  illness on which patients were admitted was 2.0 
(0-6)  and  1.5  (0-9)  days  in  CCHF  and  non-CCHF 
patients,  respectively  and  the difference was not sta-
tistically significant (p> 0.05). The median elapsed time 
from admission of  cases to the conclusion of  RT-PCR 
and/or ELISA was 3.0 (1-6) days for CCHF cases, while 
it was 5.0 ± (2-10) days for non-CCHF cases. In the 
non-CCHF group, the elapsed time was significantly 
higher than the CCHF group (p <0.05).
Discussion
The number  of  male and female CCHF cases in Tur-
key  is similar.  Two thirds of  cases   are   farmers   or 
housewives.   Housewives   in  rural   areas   work   ac-
tively particularly  in farming and animal husbandry 
in Turkey 23-27. No housewives  were included in  our 
study, because, housewives  live mostly in rural areas 
and work in animal husbandry and farming sector. Be-
tween 2004-2007, the proportion of  health care work-
ers among CCHF cases was 0.4% in Turkey and sero-
prevalence among healthcare workers in endemic areas 
was 2% 6, 28. In our study, there was no health care work-
er. In Iran, 34.3% of  the 2536 cases with suspicion of  
CCHF was confirmed as CCHF and the probability of  
positive results for male samples was higher than that 
for female samples during 1999-2012 20. In our study, 
the proportion of  CCHF cases was 46.3% among cases 
with a preliminary diagnosis of  CCHF and there was no 
significant difference between the two groups in terms 
of  gender (p>0.05).
The fatality rate of  CCHF was approximately 15–30% 
1-10. The mean fatality rate for Turkey was about 5% 
in 2002-2007. The fatality rate was calculated as 8.8% 
in Bolu Province located in the Western Black Sea re-
gion of  Turkey in 2006-2012 21. In our hospital, 342 
CCHF cases were diagnosed in 2005-2010 and the fatal-
ity rate was found to be 2.9%29. In 2013, we diagnosed 
19 CCHF cases and the fatality rate was 5.3%. Although 
this rate was similar to that of  other parts of  Turkey, 
the differences among studies in different regions may 
be associated with the use of  ribavirin. Compared to 
previous years, the number of  cases was lower and the 
fatality rate was higher  in  our  hospital  in  2013.  This 
may  be  explained  by  the  use  of   ribavirin, because, 
three of  19 CCHF cases received oral ribavirin in 2013 
while the rate of  the use of  ribavirin was approximately 
85% in 2005-2010 in our hospital 29.
CCHF cases usually occurred between April and Sep-
tember, with a peak incidence in June and July 2, 4, 9, 10. 
In Turkey, the frequency of  tick-bite / tick contact in 
CCHF cases in 2007-2009 was 68.9%, and 84.1% of  
such cases occured during May, June and July 6. In 2013, 
the first CCHF case at our hospital was detected in April 
as expected. However, it was interesting that the peak 
incidence was in May and there were no cases detected 
in August. However, besides our hospital, there is one 
more private  hospital  that  could  follow  up cases  with 
CCHF  in Kastamonu.  Therefore, CCHF  cases  might 
have  been  admitted  to this  hospital,  or a hospital 
outside  of  Kastamonu, during the same period.
The most common  symptoms  in cases  with CCHF 
are fever, headache,  myalgia, nausea, vomiting, abdom-
inal pain, diarrhea and hemorragic findings, respec-
tively6,9,10. In some studies, fever, bleeding, vomiting, 
headache and diarrhea were reported more frequently 
in cases with CCHF than non-CCHF cases20, 21. In our 
study, there were no significant differences between the 
two groups in terms of  clinical findings during admis-
sion (p>0.05). Unexpectedly, there were no hemor-
rhagic findings among CCHF cases during admission. 
This may be due to the fact that patients were in early 
phase of  CCHF. Because, in our study, the median day 
of  illness on which CCHF cases were admitted was 2.0 
days. On the other hand, this may be due to the fact 
that cases with hemorrhagic findings were admitted to 
other clinics/hospitals and/or they were misdiagnosed 
in other departments.
Thrombocytopenia, leucopenia, increased AST-ALT, 
CK and LDH levels are the most common  laboratory 
findings in CCHF  cases6,  9,  10. In some studies, throm-
bocytopenia,   increased   AST-ALT   and   LDH   levels 
were   reported   more commonly among cases with 
CCHF than non-CCHF cases 20, 21. In our study, CK 
elevation was more common in CCHF cases (p<0.05), 
but, other laboratory findings during  admission  were 
found  to  be  similar  between  the  two  groups 
(p>0.05). Increased CK levels during admission in cas-
es with CCHF may help to distinguish similar cases but 
our CCHF cases had milder clinical signs. This may ac-
count for the results of  other laboratory investigations 
that were not significantly different.
A specific diagnosis may be made by testing a serum 
specimen for viral RNA by RT- PCR and for virus-spe-
cific IgM and/or IgG by ELISA or other methods. In 
general, virus can be detected for up to two weeks after 
the first clinical symptoms occur. An IgM antibody re-
sponse is detectable from the fourth day after the onset 
of  disease for up to four months. IgG antibodies can 
be found from sixth day after the incubation period  up 
to  five  years 2,  4,  9,  10. In  our  study,  the  mean  elapsed 
time  from  the admission of  cases to the conclusion of  
the tests was higher for non-CCHF cases than  CCHF 
cases.  As  our  hospital  is  a  secondary  care  hospi-
tal  having  limited diagnostic facilities, excluding the 
diagnosis of  CCHF can take more time. Therefore, 
performing tests for the differential diagnosis may be 
advisable during this time.
CCHFV transmission may occur by the bite of  an 
infected tick or by exposure to the body fluids  of  a 
viremic  animal  or a CCHF  case2,  4,  9,  10. Tick bites  and 
animal husbandry have been reported as risk factors 
for seropositivity and a history of  tick bite and animal 
husbandry was identified in majority of  CCHF cases in 
Turkey. Seroprevalence  was 10% in individuals  with 
a history of  tick bite. Seroprevalence was reported as 
10–19.6% in endemic regions of  Turkey. Seropositivity 
in individuals with a history of  farming, animal hus-
bandry, contact with animals and contact with ticks was 
80%, 70%, 76% and 70% respectively6,  8,  30,  31-34. In Iran, 
contact  with infected humans and animals was higher 
in the CCHF group than the non-CCHF group, but, 
a history of  tick bite was not a risk factor20. Similarly, 
contact with animals was more commonly reported in 
CCHF cases than non-CCHF cases, but, a history of  
tick bite was similar between the two groups in Bolu, 
Turkey 21. We found that the frequency of  tick bites was 
significantly higher in CCHF cases than non-CCHF 
cases (p<0.05).
The efficacy of  ribavirin in antiviral treatment remains 
controversial.  Although most reports claimed a ther-
apeutic benefit about ribavirin use, the quality of  the 
evidence was low. In general, treatment of  CCHF is 
mainly supportive therapy9, 10, 35, 36. In our study, the case 
who died did not receive ribarivin therapy and three of  
CCHF cases received oral ribavirin.
This study has several limitations. First, the study re-
ports a retrospective, one-year, single center data and 
includes  only  participants who were admitted to our 
hospital. Second limitation is small sample size and low 
study power. Significant differences between the two 
groups may have not been detected.  Third, the study 
evaluates characteristics of  cases during admission, the 
patients were not evaluated during the course of  the 
disease. Despite these limitations, all patients admitted 
to our hospital were  included the study. There are a few 
studies evaluating cases with a preliminary diagnosis  of  






Table 3. The distribution of epidemiological characteristics of cases with  
a preliminary diagnosis of Crimean-Congo hemorrhagic fever within the last 15 days. 






Epidemiological characteristics % (n) % (n)  
 







Contact with animals 89.5 (17) 77.3 (17) p>0.05 
Tick bite 84.2 (16) 27.3 (6) P<0.05 
Contact with body fluids, tissue  







Traveling to rural areas 10.5 (2) 18.2 (4) p>0.05 
Contact with CCHF cases 0.0 (0) 0.0 (0) p>0.05 
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The disease still remains important in endemic regions 
of  Turkey, although the fatality rate is low (5%) in Tur-
key than other endemic  countries1-10, 19,  21,  29. The clini-
cal presentation is not diagnostic and physical examina-
tion and laboratory findings are not specific especially 
in cases without hemorrhagic findings2-4, 8-10. In areas 
endemic for CCHF, clinicians should be aware of  the 
possibility of  other diseases in cases with a  preliminary 
diagnosis  of   CCHF  and  should  determine  and  con-
sider  clinical, laboratory and epidemiological character-
istics during admission of  such cases. 
Conclusion
In cases with a preliminary diagnosis of  CCHF, espe-
cially in cases without a history of  tick bite and with 
normal CK levels  during  admission,  performing  tests 
for the differential diagnosis may be advisable without 
waiting for the results of  RT-PCR and ELISA tests for 
CCHF. This may help reduce the number of  cases mis-
diagnosed as CCHF and increase the overall probability 
of  detecting CCHF cases.
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